AR046172A1 - Pirazolopiridinas y sus analogos; composiciones farmaceuticas que los contienen y su uso en la inhibicion de la biosintesis de citocinas - Google Patents
Pirazolopiridinas y sus analogos; composiciones farmaceuticas que los contienen y su uso en la inhibicion de la biosintesis de citocinasInfo
- Publication number
- AR046172A1 AR046172A1 ARP040103583A AR046172A1 AR 046172 A1 AR046172 A1 AR 046172A1 AR P040103583 A ARP040103583 A AR P040103583A AR 046172 A1 AR046172 A1 AR 046172A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- alkyl
- alkenyl
- hydrogen
- substituted
- Prior art date
Links
- 230000015572 biosynthetic process Effects 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000005764 inhibitory process Effects 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 22
- 125000003342 alkenyl group Chemical group 0.000 abstract 14
- 229910052739 hydrogen Inorganic materials 0.000 abstract 13
- 239000001257 hydrogen Substances 0.000 abstract 13
- 125000000304 alkynyl group Chemical group 0.000 abstract 12
- 125000000623 heterocyclic group Chemical group 0.000 abstract 12
- 125000001072 heteroaryl group Chemical group 0.000 abstract 11
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 11
- 125000002947 alkylene group Chemical group 0.000 abstract 10
- 125000003545 alkoxy group Chemical group 0.000 abstract 8
- 125000003118 aryl group Chemical group 0.000 abstract 8
- 229910052736 halogen Inorganic materials 0.000 abstract 8
- 150000002367 halogens Chemical class 0.000 abstract 8
- 125000001188 haloalkyl group Chemical group 0.000 abstract 7
- 125000004450 alkenylene group Chemical group 0.000 abstract 6
- 125000004419 alkynylene group Chemical group 0.000 abstract 6
- 125000000732 arylene group Chemical group 0.000 abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 6
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 6
- 125000005549 heteroarylene group Chemical group 0.000 abstract 6
- 125000004414 alkyl thio group Chemical group 0.000 abstract 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 5
- 125000001424 substituent group Chemical group 0.000 abstract 5
- 150000001412 amines Chemical class 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- 125000003282 alkyl amino group Chemical group 0.000 abstract 3
- 125000002877 alkyl aryl group Chemical group 0.000 abstract 3
- 125000005529 alkyleneoxy group Chemical group 0.000 abstract 3
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 3
- 125000005532 aryl alkyleneoxy group Chemical group 0.000 abstract 3
- 125000004104 aryloxy group Chemical group 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 3
- 125000005553 heteroaryloxy group Chemical group 0.000 abstract 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 3
- -1 nitro, hydroxy, mercapto Chemical group 0.000 abstract 3
- 125000004043 oxo group Chemical group O=* 0.000 abstract 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 229910052801 chlorine Inorganic materials 0.000 abstract 2
- 239000000460 chlorine Substances 0.000 abstract 2
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 229910052731 fluorine Chemical group 0.000 abstract 2
- 239000011737 fluorine Chemical group 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 230000002452 interceptive effect Effects 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- UCFFGYASXIPWPD-UHFFFAOYSA-N methyl hypochlorite Chemical group COCl UCFFGYASXIPWPD-UHFFFAOYSA-N 0.000 abstract 2
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 239000002955 immunomodulating agent Substances 0.000 abstract 1
- 229940121354 immunomodulator Drugs 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 230000001613 neoplastic effect Effects 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Neurology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50835203P | 2003-10-03 | 2003-10-03 | |
| US55468004P | 2004-03-19 | 2004-03-19 | |
| US60330304P | 2004-08-20 | 2004-08-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR046172A1 true AR046172A1 (es) | 2005-11-30 |
Family
ID=34891119
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040103583 AR046172A1 (es) | 2003-10-03 | 2004-10-01 | Pirazolopiridinas y sus analogos; composiciones farmaceuticas que los contienen y su uso en la inhibicion de la biosintesis de citocinas |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9145410B2 (enExample) |
| EP (1) | EP1696912B1 (enExample) |
| JP (2) | JP2007508305A (enExample) |
| KR (2) | KR20060120069A (enExample) |
| AR (1) | AR046172A1 (enExample) |
| AU (1) | AU2004315876B2 (enExample) |
| BR (1) | BRPI0414867A (enExample) |
| CA (1) | CA2540598C (enExample) |
| ES (1) | ES2584863T3 (enExample) |
| IL (1) | IL174647A (enExample) |
| MY (1) | MY146124A (enExample) |
| NZ (1) | NZ546274A (enExample) |
| SG (1) | SG149829A1 (enExample) |
| TW (1) | TW200526656A (enExample) |
| WO (1) | WO2005079195A2 (enExample) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6797718B2 (en) | 2002-06-07 | 2004-09-28 | 3M Innovative Properties Company | Ether substituted imidazopyridines |
| CA2537763A1 (en) | 2003-09-05 | 2005-03-17 | 3M Innovative Properties Company | Treatment for cd5+ b cell lymphoma |
| US7544697B2 (en) | 2003-10-03 | 2009-06-09 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and analogs thereof |
| EP1673087B1 (en) | 2003-10-03 | 2015-05-13 | 3M Innovative Properties Company | Alkoxy substituted imidazoquinolines |
| WO2005051317A2 (en) | 2003-11-25 | 2005-06-09 | 3M Innovative Properties Company | Substituted imidazo ring systems and methods |
| US7915281B2 (en) | 2004-06-18 | 2011-03-29 | 3M Innovative Properties Company | Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method |
| PL1789042T3 (pl) | 2004-09-02 | 2012-09-28 | 3M Innovative Properties Co | Układy pierścieni 1-alkoksy 1H-imidazo i sposoby |
| EP1830876B1 (en) | 2004-12-30 | 2015-04-08 | Meda AB | Use of imiquimod for the treatment of cutaneous metastases derived from a breast cancer tumor |
| ES2392647T3 (es) | 2004-12-30 | 2012-12-12 | 3M Innovative Properties Company | Compuestos tetracíclicos quirales que inducen la biosíntesis de interferón |
| EP1831221B1 (en) | 2004-12-30 | 2012-08-08 | 3M Innovative Properties Company | Substituted chiral fused 1,2 imidazo 4,5-c ring compounds |
| AU2006210392A1 (en) | 2005-02-04 | 2006-08-10 | Coley Pharmaceutical Group, Inc. | Aqueous gel formulations containing immune response modifiers |
| EP1846405A2 (en) | 2005-02-11 | 2007-10-24 | 3M Innovative Properties Company | Oxime and hydroxylamine substituted imidazo 4,5-c ring compounds and methods |
| JP2008535832A (ja) | 2005-04-01 | 2008-09-04 | コーリー ファーマシューティカル グループ，インコーポレイテッド | ピラゾロピリジン−１，４−ジアミン、およびそのアナログ |
| US7943636B2 (en) * | 2005-04-01 | 2011-05-17 | 3M Innovative Properties Company | 1-substituted pyrazolo (3,4-C) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases |
| WO2007100634A2 (en) | 2006-02-22 | 2007-09-07 | 3M Innovative Properties Company | Immune response modifier conjugates |
| US7906506B2 (en) | 2006-07-12 | 2011-03-15 | 3M Innovative Properties Company | Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods |
| US20080149123A1 (en) * | 2006-12-22 | 2008-06-26 | Mckay William D | Particulate material dispensing hairbrush with combination bristles |
| UA103195C2 (uk) | 2008-08-11 | 2013-09-25 | Глаксосмитклайн Ллк | Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань |
| WO2011089400A1 (en) | 2010-01-22 | 2011-07-28 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Inhibitors of pi3 kinase |
| SMT201700182T1 (it) | 2010-08-17 | 2017-05-08 | 3M Innovative Properties Company | Composizioni di composti modificanti la risposta immunitaria lipidati, formulazioni e metodi |
| AU2012244549B2 (en) * | 2011-04-21 | 2017-04-20 | Origenis Gmbh | Heterocyclic compounds as kinase inhibitors |
| JP6415979B2 (ja) | 2011-06-03 | 2018-10-31 | スリーエム イノベイティブ プロパティズ カンパニー | ヒドラジノ１ｈ−イミダゾキノリン−４−アミン及びこれから調製された複合体 |
| KR101916928B1 (ko) | 2011-07-22 | 2018-11-08 | 글락소스미스클라인 엘엘씨 | 조성물 |
| CA2880576A1 (en) * | 2012-08-24 | 2014-02-27 | Glaxosmithkline Llc | Pyrazolopyrimidine compounds |
| US10000482B2 (en) | 2012-10-19 | 2018-06-19 | Origenis Gmbh | Kinase inhibitors |
| CN104780924B (zh) | 2012-11-20 | 2016-09-14 | 葛兰素史克有限责任公司 | 干扰素诱导剂化合物 |
| PT2922549T (pt) | 2012-11-20 | 2017-09-01 | Glaxosmithkline Llc | Novos compostos |
| AU2013348216B2 (en) | 2012-11-20 | 2016-10-13 | Glaxosmithkline Llc | Novel compounds |
| US20150335637A1 (en) | 2013-01-07 | 2015-11-26 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating cutaneous t cell lymphoma |
| CA2936375A1 (en) | 2014-01-10 | 2015-07-16 | Shanghai Birdie Biotech, Inc. | Compounds and compositions for treating her2 positive tumors |
| FI4001311T3 (fi) | 2014-07-09 | 2026-01-27 | Birdie Biopharmaceuticals Inc | Pd-l1/pd-1-vasta-aineiden yhdistelmiä kasvaimien hoitoon |
| US10526309B2 (en) | 2015-10-02 | 2020-01-07 | The University Of North Carolina At Chapel Hill | Pan-TAM inhibitors and Mer/Axl dual inhibitors |
| CN106943596A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技（北京）有限公司 | 用于治疗肿瘤的抗-cd20组合 |
| CN115252792A (zh) | 2016-01-07 | 2022-11-01 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-egfr组合 |
| KR102392974B1 (ko) | 2016-05-16 | 2022-05-02 | 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) | Tlr 작용제를 함유하는 제제 및 사용 방법 |
| MX2018013640A (es) | 2016-05-16 | 2019-08-01 | Infectious Disease Res Inst | Liposomas pegiladas y metodos de uso. |
| AU2017321609C1 (en) | 2016-08-30 | 2023-11-09 | Dana-Farber Cancer Institute, Inc. | Drug delivery compositions and uses thereof |
| CN108794467A (zh) | 2017-04-27 | 2018-11-13 | 博笛生物科技有限公司 | 2-氨基-喹啉衍生物 |
| AR111760A1 (es) | 2017-05-19 | 2019-08-14 | Novartis Ag | Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral |
| CN110769827A (zh) | 2017-06-23 | 2020-02-07 | 博笛生物科技有限公司 | 药物组合物 |
| EP3759129A1 (en) | 2018-02-28 | 2021-01-06 | Pfizer Inc | Il-15 variants and uses thereof |
| CA3097865A1 (en) | 2018-04-25 | 2019-10-31 | Innate Tumor Immunity, Inc. | Nlrp3 modulators |
| ES2984950T3 (es) | 2018-05-23 | 2024-10-31 | Pfizer | Anticuerpos específicos para CD3 y sus usos |
| SG11202010934SA (en) | 2018-05-23 | 2020-12-30 | Pfizer | Antibodies specific for gucy2c and uses thereof |
| WO2020128893A1 (en) | 2018-12-21 | 2020-06-25 | Pfizer Inc. | Combination treatments of cancer comprising a tlr agonist |
| CN114269749B (zh) | 2019-06-10 | 2024-10-01 | 苏特罗生物制药公司 | 5H-吡咯并[3,2-d]嘧啶-2,4-二氨基化合物及其抗体偶联物 |
| CN114746420A (zh) * | 2019-06-17 | 2022-07-12 | 苏特罗生物制药公司 | 用于癌症治疗和诊断的作为Toll样受体（TLR）7/8激动剂的1-(4-(氨基甲基)苄基)-2-丁基-2H-吡唑并[3,4-c]喹啉-4-胺衍生物及相关化合物以及其抗体药物偶联物 |
| CN115397853A (zh) | 2019-12-17 | 2022-11-25 | 辉瑞大药厂 | 对cd47、pd-l1具特异性的抗体及其用途 |
| WO2022009157A1 (en) | 2020-07-10 | 2022-01-13 | Novartis Ag | Lhc165 and spartalizumab combinations for treating solid tumors |
| KR20230022246A (ko) | 2020-07-17 | 2023-02-14 | 화이자 인코포레이티드 | 치료 항체 및 그의 용도 |
| WO2025104289A1 (en) | 2023-11-17 | 2025-05-22 | Medincell S.A. | Antineoplastic combinations |
Family Cites Families (204)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3314941A (en) | 1964-06-23 | 1967-04-18 | American Cyanamid Co | Novel substituted pyridodiazepins |
| US3891660A (en) * | 1974-02-07 | 1975-06-24 | Squibb & Sons Inc | Derivatives of 1H-imidazo{8 4,5-c{9 pyridine-7-carboxylic acids and esters |
| US4221910A (en) * | 1978-09-15 | 1980-09-09 | Newport Pharmaceuticals International, Inc. | 9-(Hydroxy alkyl)purines |
| US4221909A (en) * | 1978-09-15 | 1980-09-09 | Sloan-Kettering Institute For Cancer Research | P-Acetamidobenzoic acid salts of 9-(hydroxyalkyl) purines |
| US4340726A (en) * | 1980-03-14 | 1982-07-20 | Newport Pharmaceuticals International, Inc. | Esters |
| IL73534A (en) * | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
| ZA848968B (en) | 1983-11-18 | 1986-06-25 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines |
| JPS6229524A (ja) * | 1985-08-01 | 1987-02-07 | Asahi Chem Ind Co Ltd | 悪性腫瘍治療用刺激剤 |
| US4826986A (en) | 1986-06-16 | 1989-05-02 | Eli Lilly And Company | 6-Oxo-trans-octa- and decahydroquinolines |
| CA1293727C (en) * | 1986-08-26 | 1991-12-31 | Catherine Rose Kostlan | 9-deazaguanines |
| JP2701281B2 (ja) * | 1988-01-22 | 1998-01-21 | 吉富製薬株式会社 | ピラゾロピリジン化合物 |
| US5238944A (en) | 1988-12-15 | 1993-08-24 | Riker Laboratories, Inc. | Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine |
| US5756747A (en) | 1989-02-27 | 1998-05-26 | Riker Laboratories, Inc. | 1H-imidazo 4,5-c!quinolin-4-amines |
| US5037986A (en) | 1989-03-23 | 1991-08-06 | Minnesota Mining And Manufacturing Company | Olefinic 1H-imidazo[4,5-c]quinolin-4-amines |
| US4929624A (en) | 1989-03-23 | 1990-05-29 | Minnesota Mining And Manufacturing Company | Olefinic 1H-imidazo(4,5-c)quinolin-4-amines |
| NZ232740A (en) | 1989-04-20 | 1992-06-25 | Riker Laboratories Inc | Solution for parenteral administration comprising a 1h-imidazo(4,5-c) quinolin-4-amine derivative, an acid and a tonicity adjuster |
| US4988815A (en) | 1989-10-26 | 1991-01-29 | Riker Laboratories, Inc. | 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines |
| HU217080B (hu) | 1990-10-05 | 1999-11-29 | Minnesota Mining And Manufacturing Co. | Új eljárás imidazo[4,5-c]kinolin-4-amin-származékok előállítására |
| US5175296A (en) | 1991-03-01 | 1992-12-29 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-c]quinolin-4-amines and processes for their preparation |
| US5389640A (en) | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
| US5268376A (en) | 1991-09-04 | 1993-12-07 | Minnesota Mining And Manufacturing Company | 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
| US5266575A (en) | 1991-11-06 | 1993-11-30 | Minnesota Mining And Manufacturing Company | 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines |
| IL105325A (en) | 1992-04-16 | 1996-11-14 | Minnesota Mining & Mfg | Immunogen/vaccine adjuvant composition |
| JP2997828B2 (ja) * | 1992-07-30 | 2000-01-11 | 株式会社大塚製薬工場 | キノリン及びナフチリジン誘導体 |
| US5395937A (en) | 1993-01-29 | 1995-03-07 | Minnesota Mining And Manufacturing Company | Process for preparing quinoline amines |
| AU681687B2 (en) | 1993-07-15 | 1997-09-04 | Minnesota Mining And Manufacturing Company | Imidazo(4,5-c)pyridin-4-amines |
| US5648516A (en) | 1994-07-20 | 1997-07-15 | Minnesota Mining And Manufacturing Company | Fused cycloalkylimidazopyridines |
| US5352784A (en) | 1993-07-15 | 1994-10-04 | Minnesota Mining And Manufacturing Company | Fused cycloalkylimidazopyridines |
| US5644063A (en) | 1994-09-08 | 1997-07-01 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-c]pyridin-4-amine intermediates |
| US5482936A (en) | 1995-01-12 | 1996-01-09 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-C]quinoline amines |
| JPH09176116A (ja) | 1995-12-27 | 1997-07-08 | Toray Ind Inc | 複素環誘導体およびその医薬用途 |
| JPH09208584A (ja) | 1996-01-29 | 1997-08-12 | Terumo Corp | アミド誘導体、およびそれを含有する医薬製剤、および合成中間体 |
| US5693811A (en) | 1996-06-21 | 1997-12-02 | Minnesota Mining And Manufacturing Company | Process for preparing tetrahdroimidazoquinolinamines |
| US5741908A (en) | 1996-06-21 | 1998-04-21 | Minnesota Mining And Manufacturing Company | Process for reparing imidazoquinolinamines |
| AU724042B2 (en) | 1996-10-25 | 2000-09-07 | Minnesota Mining And Manufacturing Company | Immune response modifier compounds for treatment of TH2 mediated and related diseases |
| US5939090A (en) | 1996-12-03 | 1999-08-17 | 3M Innovative Properties Company | Gel formulations for topical drug delivery |
| WO1998030562A1 (en) | 1997-01-09 | 1998-07-16 | Terumo Kabushiki Kaisha | Novel amide derivatives and intermediates for the synthesis thereof |
| JPH10298181A (ja) * | 1997-04-25 | 1998-11-10 | Sumitomo Pharmaceut Co Ltd | タイプ２ヘルパーｔ細胞選択的免疫応答抑制剤 |
| JPH1180156A (ja) | 1997-09-04 | 1999-03-26 | Hokuriku Seiyaku Co Ltd | １−（置換アリール）アルキル−１ｈ−イミダゾピリジン−４−アミン誘導体 |
| UA67760C2 (uk) | 1997-12-11 | 2004-07-15 | Міннесота Майнінг Енд Мануфакчурінг Компані | Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки |
| JPH11222432A (ja) | 1998-02-03 | 1999-08-17 | Terumo Corp | インターフェロンを誘起するアミド誘導体を含有する外用剤 |
| US6110929A (en) | 1998-07-28 | 2000-08-29 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
| JP2000119271A (ja) | 1998-08-12 | 2000-04-25 | Hokuriku Seiyaku Co Ltd | １ｈ―イミダゾピリジン誘導体 |
| US6486168B1 (en) | 1999-01-08 | 2002-11-26 | 3M Innovative Properties Company | Formulations and methods for treatment of mucosal associated conditions with an immune response modifier |
| US20020058674A1 (en) | 1999-01-08 | 2002-05-16 | Hedenstrom John C. | Systems and methods for treating a mucosal surface |
| ATE304852T1 (de) | 1999-01-08 | 2005-10-15 | 3M Innovative Properties Co | Zubereitungen, umfassend imiquimod oder andere immunantwort modifizierenden verbindungen, zur behandlung von zervikaler dysplasie |
| US6558951B1 (en) | 1999-02-11 | 2003-05-06 | 3M Innovative Properties Company | Maturation of dendritic cells with immune response modifying compounds |
| JP2000247884A (ja) | 1999-03-01 | 2000-09-12 | Sumitomo Pharmaceut Co Ltd | アラキドン酸誘発皮膚疾患治療剤 |
| US6541485B1 (en) | 1999-06-10 | 2003-04-01 | 3M Innovative Properties Company | Urea substituted imidazoquinolines |
| US6451810B1 (en) | 1999-06-10 | 2002-09-17 | 3M Innovative Properties Company | Amide substituted imidazoquinolines |
| US6573273B1 (en) | 1999-06-10 | 2003-06-03 | 3M Innovative Properties Company | Urea substituted imidazoquinolines |
| US6756382B2 (en) | 1999-06-10 | 2004-06-29 | 3M Innovative Properties Company | Amide substituted imidazoquinolines |
| US6331539B1 (en) | 1999-06-10 | 2001-12-18 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
| US6916925B1 (en) | 1999-11-05 | 2005-07-12 | 3M Innovative Properties Co. | Dye labeled imidazoquinoline compounds |
| US6376669B1 (en) | 1999-11-05 | 2002-04-23 | 3M Innovative Properties Company | Dye labeled imidazoquinoline compounds |
| US6894060B2 (en) | 2000-03-30 | 2005-05-17 | 3M Innovative Properties Company | Method for the treatment of dermal lesions caused by envenomation |
| US20020055517A1 (en) | 2000-09-15 | 2002-05-09 | 3M Innovative Properties Company | Methods for delaying recurrence of herpes virus symptoms |
| JP2002145777A (ja) | 2000-11-06 | 2002-05-22 | Sumitomo Pharmaceut Co Ltd | アラキドン酸誘発皮膚疾患治療剤 |
| US6664260B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Heterocyclic ether substituted imidazoquinolines |
| US6525064B1 (en) | 2000-12-08 | 2003-02-25 | 3M Innovative Properties Company | Sulfonamido substituted imidazopyridines |
| US6664264B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
| US6660735B2 (en) | 2000-12-08 | 2003-12-09 | 3M Innovative Properties Company | Urea substituted imidazoquinoline ethers |
| US6545017B1 (en) | 2000-12-08 | 2003-04-08 | 3M Innovative Properties Company | Urea substituted imidazopyridines |
| US6667312B2 (en) | 2000-12-08 | 2003-12-23 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
| US6677348B2 (en) | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Aryl ether substituted imidazoquinolines |
| WO2006091720A2 (en) | 2000-12-08 | 2006-08-31 | 3M Innovative Properties Company | Compositions and methods for targeted delivery of immune response modifiers |
| US6677347B2 (en) | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamido ether substituted imidazoquinolines |
| US6660747B2 (en) | 2000-12-08 | 2003-12-09 | 3M Innovative Properties Company | Amido ether substituted imidazoquinolines |
| US20020107262A1 (en) | 2000-12-08 | 2002-08-08 | 3M Innovative Properties Company | Substituted imidazopyridines |
| UA75622C2 (en) | 2000-12-08 | 2006-05-15 | 3M Innovative Properties Co | Aryl ether substituted imidazoquinolines, pharmaceutical composition based thereon |
| US6545016B1 (en) | 2000-12-08 | 2003-04-08 | 3M Innovative Properties Company | Amide substituted imidazopyridines |
| US6664265B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Amido ether substituted imidazoquinolines |
| KR100455713B1 (ko) | 2001-01-29 | 2004-11-06 | 호남석유화학 주식회사 | 올레핀 중합용 다중핵 메탈로센 촉매 및 이를 이용한중합방법 |
| US7226928B2 (en) | 2001-06-15 | 2007-06-05 | 3M Innovative Properties Company | Methods for the treatment of periodontal disease |
| JP2005501550A (ja) | 2001-08-30 | 2005-01-20 | スリーエム イノベイティブ プロパティズ カンパニー | 免疫反応調整剤分子を用いた形質細胞様樹状細胞を成熟させる方法 |
| WO2003030902A1 (en) | 2001-10-09 | 2003-04-17 | Tularik Inc. | Imidazole derivates as anti-inflammatory agents |
| US20030139364A1 (en) | 2001-10-12 | 2003-07-24 | University Of Iowa Research Foundation | Methods and products for enhancing immune responses using imidazoquinoline compounds |
| ATE416771T1 (de) | 2001-11-16 | 2008-12-15 | 3M Innovative Properties Co | N-ä4-(4-amino-2-ethyl-1h-imidazoä4,5-cüchinolin 1-yl)butylümethanesulfonamide, diese enthaltende pharmazeutische zusammensetzung und deren verwendung |
| US20030199538A1 (en) | 2001-11-29 | 2003-10-23 | 3M Innovative Properties Company | Pharmaceutical formulation comprising an immune response modifier |
| US6677349B1 (en) | 2001-12-21 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
| US7030129B2 (en) | 2002-02-22 | 2006-04-18 | 3M Innovative Properties Company | Method of reducing and treating UVB-induced immunosuppression |
| WO2003080114A2 (en) | 2002-03-19 | 2003-10-02 | Powdermed Limited | Imidazoquinoline adjuvants for vaccines |
| GB0211649D0 (en) | 2002-05-21 | 2002-07-03 | Novartis Ag | Organic compounds |
| JP2005531599A (ja) | 2002-05-29 | 2005-10-20 | スリーエム イノベイティブ プロパティズ カンパニー | イミダゾ［４，５−ｃ］ピリジン−４−アミンのための方法 |
| US6797718B2 (en) | 2002-06-07 | 2004-09-28 | 3M Innovative Properties Company | Ether substituted imidazopyridines |
| CA2493227A1 (en) | 2002-07-23 | 2004-01-29 | Biogal Gyogyszergyar Rt. | Preparation of 1h-imidazo[4,5-c]quinolin-4-amines via1h-imidazo [4,5-c]quinolin-4-phthalimide intermediates |
| ATE357445T1 (de) | 2002-07-26 | 2007-04-15 | Teva Gyogyszergyar Zartkoeruee | Darstellung von 1h-imidazo(4,5-c)chinolin-4- aminen über neue 1h-imidazo(4,5-c)chinolin-4- cyano- und 1h-imidazo(4,5-c)chinolin-4-carboxamid intermediate |
| PT1545597E (pt) | 2002-08-15 | 2010-12-29 | 3M Innovative Properties Co | Composições imunoestimulantes e métodos de estimulação de uma resposta imunológica |
| EP1542688A4 (en) | 2002-09-26 | 2010-06-02 | 3M Innovative Properties Co | 1H-imidazo dimers |
| CA2502429A1 (en) | 2002-10-31 | 2004-05-21 | Amgen Inc. | Antiinflammation agents |
| WO2004053452A2 (en) | 2002-12-11 | 2004-06-24 | 3M Innovative Properties Company | Assays relating to toll-like receptor activity |
| AU2003287324A1 (en) | 2002-12-11 | 2004-06-30 | 3M Innovative Properties Company | Gene expression systems and recombinant cell lines |
| WO2004058759A1 (en) | 2002-12-20 | 2004-07-15 | 3M Innovative Properties Company | Aryl / hetaryl substituted imidazoquinolines |
| WO2004060319A2 (en) | 2002-12-30 | 2004-07-22 | 3M Innovative Properties Company | Immunostimulatory combinations |
| JP2006517974A (ja) | 2003-02-13 | 2006-08-03 | スリーエム イノベイティブ プロパティズ カンパニー | Ｉｒｍ化合物およびトル様受容体８に関する方法および組成物 |
| EP1599726A4 (en) | 2003-02-27 | 2009-07-22 | 3M Innovative Properties Co | SELECTIVE MODULATION OF TLR-MEDIATED BIOLOGICAL ACTIVITY |
| EP1601365A4 (en) | 2003-03-04 | 2009-11-11 | 3M Innovative Properties Co | PROPHYLACTIC TREATMENT OF UV-INDUCED EPIDERMAL NEOPLASIA |
| US7163947B2 (en) | 2003-03-07 | 2007-01-16 | 3M Innovative Properties Company | 1-Amino 1H-imidazoquinolines |
| EP1603476A4 (en) | 2003-03-13 | 2010-01-13 | 3M Innovative Properties Co | PROCESS FOR REMOVING TATTOO |
| EP1608282A4 (en) | 2003-03-13 | 2010-12-08 | 3M Innovative Properties Co | METHODS OF DIAGNOSING SKIN LESIONS |
| KR20050109562A (ko) | 2003-03-13 | 2005-11-21 | 쓰리엠 이노베이티브 프로퍼티즈 컴파니 | 피부의 질을 개선시키는 방법 |
| US20040192585A1 (en) | 2003-03-25 | 2004-09-30 | 3M Innovative Properties Company | Treatment for basal cell carcinoma |
| EP1613956A2 (en) | 2003-03-25 | 2006-01-11 | 3M Innovative Properties Company | Selective activation of cellular activities mediated through a common toll-like receptor |
| US20040265351A1 (en) | 2003-04-10 | 2004-12-30 | Miller Richard L. | Methods and compositions for enhancing immune response |
| AU2004229478B2 (en) | 2003-04-10 | 2009-12-24 | 3M Innovative Properties Company | Delivery of immune response modifier compounds |
| EP1617845A4 (en) | 2003-04-28 | 2006-09-20 | 3M Innovative Properties Co | COMPOSITIONS AND METHODS FOR INDUCING OPOID RECEPTORS |
| US7731967B2 (en) | 2003-04-30 | 2010-06-08 | Novartis Vaccines And Diagnostics, Inc. | Compositions for inducing immune responses |
| WO2004110992A2 (en) | 2003-06-06 | 2004-12-23 | 3M Innovative Properties Company | Process for imidazo[4,5-c] pyridin-4-amines |
| US6943255B2 (en) | 2003-06-06 | 2005-09-13 | 3M Innovative Properties Company | Process for imidazo[4,5-c]pyridin-4-amines |
| MY157827A (en) | 2003-06-27 | 2016-07-29 | 3M Innovative Properties Co | Sulfonamide substituted imidazoquinolines |
| US20050106300A1 (en) | 2003-06-30 | 2005-05-19 | Purdue Research Foundation | Method for producing a material having an increased solubility in alcohol |
| BRPI0413164A (pt) | 2003-07-31 | 2006-10-03 | 3M Innovative Properties Co | composições bioativas compreendendo as triazinas |
| CN1852711A (zh) | 2003-08-05 | 2006-10-25 | 3M创新有限公司 | 使用免疫响应调节化合物的传染病预防 |
| AU2004266641A1 (en) | 2003-08-12 | 2005-03-03 | 3M Innovative Properties Company | Oxime substituted imidazo-containing compounds |
| EP1653959B1 (en) | 2003-08-14 | 2015-05-27 | 3M Innovative Properties Company | Lipid-modified immune response modifiers |
| CA2536249A1 (en) | 2003-08-25 | 2005-03-10 | 3M Innovative Properties Company | Delivery of immune response modifier compounds |
| JP2007504145A (ja) | 2003-08-25 | 2007-03-01 | スリーエム イノベイティブ プロパティズ カンパニー | 免疫刺激性の組み合わせおよび治療 |
| MY145983A (en) | 2003-08-27 | 2012-05-31 | 3M Innovative Properties Co | Aryloxy and arylalkyleneoxy substituted imidazoquinolines |
| MXPA06002408A (es) | 2003-09-02 | 2006-06-20 | 3M Innovative Properties Co | Metodos relacionados al tratamiento de condiciones asociadas a la mucosa. |
| CA2537763A1 (en) | 2003-09-05 | 2005-03-17 | 3M Innovative Properties Company | Treatment for cd5+ b cell lymphoma |
| WO2005025583A2 (en) | 2003-09-05 | 2005-03-24 | Anadys Pharmaceuticals, Inc. | Tlr7 ligands for the treatment of hepatitis c |
| JP2007505629A (ja) | 2003-09-17 | 2007-03-15 | スリーエム イノベイティブ プロパティズ カンパニー | Ｔｌｒ遺伝子発現の選択的調節 |
| CA2536530A1 (en) | 2003-10-01 | 2005-04-14 | Taro Pharmaceuticals U.S.A., Inc. | Method of preparing 4-amino-1h-imidazo(4,5-c)quinolines and acid addition salts thereof |
| EP1673087B1 (en) | 2003-10-03 | 2015-05-13 | 3M Innovative Properties Company | Alkoxy substituted imidazoquinolines |
| US7544697B2 (en) | 2003-10-03 | 2009-06-09 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and analogs thereof |
| US20090075980A1 (en) | 2003-10-03 | 2009-03-19 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and Analogs Thereof |
| WO2005041891A2 (en) | 2003-10-31 | 2005-05-12 | 3M Innovative Properties Company | Neutrophil activation by immune response modifier compounds |
| ITMI20032121A1 (it) | 2003-11-04 | 2005-05-05 | Dinamite Dipharma Spa In Forma Abbr Eviata Dipharm | Procedimento per la preparazione di imiquimod e suoi intermedi |
| CN1906193A (zh) | 2003-11-14 | 2007-01-31 | 3M创新有限公司 | 肟取代的咪唑环化合物 |
| US8598192B2 (en) | 2003-11-14 | 2013-12-03 | 3M Innovative Properties Company | Hydroxylamine substituted imidazoquinolines |
| AR046845A1 (es) | 2003-11-21 | 2005-12-28 | Novartis Ag | Derivados de 1h-imidazo[4,5-c]quinolina para tratamiento de enfermedades dependientes de las proteino-quinasas |
| CN1902200A (zh) | 2003-11-21 | 2007-01-24 | 诺瓦提斯公司 | 用做蛋白激酶抑制剂的1h－咪唑并喹啉类衍生物 |
| CA2547085A1 (en) | 2003-11-25 | 2005-06-09 | 3M Innovative Properties Company | Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines |
| WO2005051317A2 (en) | 2003-11-25 | 2005-06-09 | 3M Innovative Properties Company | Substituted imidazo ring systems and methods |
| JP2007513165A (ja) | 2003-12-02 | 2007-05-24 | スリーエム イノベイティブ プロパティズ カンパニー | Ｉｒｍ化合物を含む併用薬および治療方法 |
| JP2007513170A (ja) | 2003-12-04 | 2007-05-24 | スリーエム イノベイティブ プロパティズ カンパニー | スルホン置換イミダゾ環エーテル |
| WO2005066170A1 (en) | 2003-12-29 | 2005-07-21 | 3M Innovative Properties Company | Arylalkenyl and arylalkynyl substituted imidazoquinolines |
| CN1922178A (zh) | 2003-12-29 | 2007-02-28 | 3M创新有限公司 | 哌嗪、[1, 4 ]二氮杂环庚烷([1,4]diazepane ) 、[1, 4 ]二氮杂环辛烷([1, 4]diazocane)、和[1,5]二氮杂环辛烷([1,5] diazocane) 稠合的咪唑并环化合物 |
| WO2005067500A2 (en) | 2003-12-30 | 2005-07-28 | 3M Innovative Properties Company | Enhancement of immune responses |
| EP1699788A2 (en) | 2003-12-30 | 2006-09-13 | 3M Innovative Properties Company | Imidazoquinolinyl, imidazopyridinyl and imidazonaphthyridinyl sulfonamides |
| US20050158325A1 (en) | 2003-12-30 | 2005-07-21 | 3M Innovative Properties Company | Immunomodulatory combinations |
| CA2559607C (en) | 2004-03-15 | 2013-02-19 | 3M Innovative Properties Company | Immune response modifier formulations and methods |
| TW200612932A (en) | 2004-03-24 | 2006-05-01 | 3M Innovative Properties Co | Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines |
| JP2007532572A (ja) | 2004-04-09 | 2007-11-15 | スリーエム イノベイティブ プロパティズ カンパニー | 免疫反応調整剤を送達させるための方法、組成物および調製物 |
| BRPI0510430A (pt) | 2004-04-28 | 2007-10-30 | 3M Innovative Properties Co | composições e métodos para vacinação mucosal |
| WO2005123079A2 (en) | 2004-06-14 | 2005-12-29 | 3M Innovative Properties Company | Urea substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines |
| WO2005123080A2 (en) | 2004-06-15 | 2005-12-29 | 3M Innovative Properties Company | Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines |
| US20070259907A1 (en) | 2004-06-18 | 2007-11-08 | Prince Ryan B | Aryl and arylalkylenyl substituted thiazoloquinolines and thiazolonaphthyridines |
| US7897609B2 (en) | 2004-06-18 | 2011-03-01 | 3M Innovative Properties Company | Aryl substituted imidazonaphthyridines |
| WO2006028545A2 (en) | 2004-06-18 | 2006-03-16 | 3M Innovative Properties Company | Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines |
| WO2006009832A1 (en) | 2004-06-18 | 2006-01-26 | 3M Innovative Properties Company | Substituted imidazo ring systems and methods |
| US7915281B2 (en) | 2004-06-18 | 2011-03-29 | 3M Innovative Properties Company | Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method |
| WO2006009826A1 (en) | 2004-06-18 | 2006-01-26 | 3M Innovative Properties Company | Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines |
| EP1786450A4 (en) | 2004-08-27 | 2009-11-11 | 3M Innovative Properties Co | HIV IMMUNOSTIMATORY COMPOSITIONS |
| US20060045885A1 (en) | 2004-08-27 | 2006-03-02 | Kedl Ross M | Method of eliciting an immune response against HIV |
| CA2578975A1 (en) | 2004-09-02 | 2006-03-16 | 3M Innovative Properties Company | 2-amino 1h imidazo ring systems and methods |
| PL1789042T3 (pl) | 2004-09-02 | 2012-09-28 | 3M Innovative Properties Co | Układy pierścieni 1-alkoksy 1H-imidazo i sposoby |
| WO2006026760A2 (en) | 2004-09-02 | 2006-03-09 | 3M Innovative Properties Company | 1-amino imidazo-containing compounds and methods |
| WO2006028451A1 (en) | 2004-09-03 | 2006-03-16 | 3M Innovative Properties Company | 1-amino 1-h-imidazoquinolines |
| US20080193468A1 (en) | 2004-09-08 | 2008-08-14 | Children's Medical Center Corporation | Method for Stimulating the Immune Response of Newborns |
| JP4769810B2 (ja) | 2004-09-14 | 2011-09-07 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド | イミダゾキノリン化合物 |
| JP2008515928A (ja) | 2004-10-08 | 2008-05-15 | スリーエム イノベイティブ プロパティズ カンパニー | Ｄｎａワクチンのためのアジュバント |
| US20100113565A1 (en) | 2004-12-08 | 2010-05-06 | Gorden Keith B | Immunostimulatory combinations and methods |
| EP1819364A4 (en) | 2004-12-08 | 2010-12-29 | 3M Innovative Properties Co | COMPOSITIONS, IMMUNOMODULATORY COMBINATIONS AND ASSOCIATED METHODS |
| US8080560B2 (en) | 2004-12-17 | 2011-12-20 | 3M Innovative Properties Company | Immune response modifier formulations containing oleic acid and methods |
| US20080119508A1 (en) | 2004-12-30 | 2008-05-22 | 3M Innovative Properties Company | Multi-Route Administration Of Immune Response Modifier Compounds |
| ES2392647T3 (es) | 2004-12-30 | 2012-12-12 | 3M Innovative Properties Company | Compuestos tetracíclicos quirales que inducen la biosíntesis de interferón |
| CA2592897A1 (en) | 2004-12-30 | 2006-07-13 | Takeda Pharmaceutical Company Limited | 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine ethanesulfonate and 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine methanesulfonate |
| EP1830876B1 (en) | 2004-12-30 | 2015-04-08 | Meda AB | Use of imiquimod for the treatment of cutaneous metastases derived from a breast cancer tumor |
| EP1831221B1 (en) | 2004-12-30 | 2012-08-08 | 3M Innovative Properties Company | Substituted chiral fused 1,2 imidazo 4,5-c ring compounds |
| US8436176B2 (en) | 2004-12-30 | 2013-05-07 | Medicis Pharmaceutical Corporation | Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine |
| ATE545010T1 (de) | 2005-02-02 | 2012-02-15 | Mocon Inc | Instrument und verfahren zum detektieren und melden der grösse von lecks in hermetisch abgedichteten verpackungen |
| AU2006210392A1 (en) | 2005-02-04 | 2006-08-10 | Coley Pharmaceutical Group, Inc. | Aqueous gel formulations containing immune response modifiers |
| AU2006338521A1 (en) | 2005-02-09 | 2007-10-11 | Coley Pharmaceutical Group, Inc. | Oxime and hydroxylamine substituted thiazolo(4,5-c) ring compounds and methods |
| AU2006212765B2 (en) | 2005-02-09 | 2012-02-02 | 3M Innovative Properties Company | Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines |
| AU2006213745A1 (en) | 2005-02-11 | 2006-08-17 | Coley Pharmaceutical Group, Inc. | Substituted fused [1,2]imidazo[4,5-c] ring compounds and methods |
| EP1846405A2 (en) | 2005-02-11 | 2007-10-24 | 3M Innovative Properties Company | Oxime and hydroxylamine substituted imidazo 4,5-c ring compounds and methods |
| AU2006216997A1 (en) | 2005-02-11 | 2006-08-31 | Coley Pharmaceutical Group, Inc. | Substituted imidazoquinolines and imidazonaphthyridines |
| JP2008538203A (ja) | 2005-02-23 | 2008-10-16 | コーリー ファーマシューティカル グループ，インコーポレイテッド | インターフェロンの生合成を優先的に誘導する方法 |
| EP1851220A2 (en) | 2005-02-23 | 2007-11-07 | 3M Innovative Properties Company | Hydroxyalkyl substituted imidazonaphthyridines |
| US8158794B2 (en) | 2005-02-23 | 2012-04-17 | 3M Innovative Properties Company | Hydroxyalkyl substituted imidazoquinoline compounds and methods |
| AU2006223634A1 (en) | 2005-02-23 | 2006-09-21 | Coley Pharmaceutical Group, Inc. | Hydroxyalkyl substituted imidazoquinolines |
| RU2007137960A (ru) | 2005-03-14 | 2009-04-20 | Меда Аб (Se) | СПОСОБ ЛЕЧЕНИЯ АКТИНИЧЕСКОГО КЕРАТОЗА (ВАРИАНТЫ) И 2-МЕТИЛ-1-(2-МЕТИЛПРОПИЛ)-1Н-ИМИДАЗО[4,5-c]]1,5]НАФТИРИДИН-4-АМИН В КАЧЕСТВЕ СРЕДСТВА ЛЕЧЕНИЯ АКТИНИЧЕСКОГО КЕРАТОЗА |
| EP1863813A2 (en) | 2005-04-01 | 2007-12-12 | Coley Pharmaceutical Group, Inc. | Pyrazolo[3,4-c]quinolines, pyrazolo[3,4-c]naphthyridines, analogs thereof, and methods |
| JP2008535832A (ja) | 2005-04-01 | 2008-09-04 | コーリー ファーマシューティカル グループ，インコーポレイテッド | ピラゾロピリジン−１，４−ジアミン、およびそのアナログ |
| US7943636B2 (en) | 2005-04-01 | 2011-05-17 | 3M Innovative Properties Company | 1-substituted pyrazolo (3,4-C) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases |
| AU2006244635A1 (en) | 2005-04-01 | 2006-11-16 | Coley Pharmaceutical Group, Inc. | Ring closing and related methods and intermediates |
| EP1874345B1 (en) | 2005-04-25 | 2012-08-15 | 3M Innovative Properties Company | Immunostimulatory compositions |
| KR20080031496A (ko) | 2005-09-02 | 2008-04-08 | 화이자 인코포레이티드 | 히드록시 치환된 1ｈ-이미다조피리딘 및 방법 |
| EA200800782A1 (ru) | 2005-09-09 | 2008-08-29 | Коли Фармасьютикал Груп, Инк. | ПРОИЗВОДНЫЕ АМИДА И КАРБАМАТА N-{2-[4-АМИНО-2-(ЭТОКСИМЕТИЛ)-1Н-ИМИДАЗОЛО[4,5-c]ХИНОЛИН-1-IL]-1,1-ДИМЕТИЛЭТИЛ}МЕТАНСУЛЬФОНАМИДА И СПОСОБЫ |
| ZA200803029B (en) | 2005-09-09 | 2009-02-25 | Coley Pharm Group Inc | Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods |
| US8889154B2 (en) | 2005-09-15 | 2014-11-18 | Medicis Pharmaceutical Corporation | Packaging for 1-(2-methylpropyl)-1H-imidazo[4,5-c] quinolin-4-amine-containing formulation |
| JP4551962B2 (ja) | 2005-09-23 | 2010-09-29 | コーリー ファーマシューティカル グループ，インコーポレイテッド | １Ｈ−イミダゾ［４，５−ｃ］ピリジンおよびその類似体のための方法 |
| CN101309687A (zh) | 2005-11-04 | 2008-11-19 | 科勒制药集团公司 | 经羟基和烷氧基取代的1h-咪唑并喹啉及其方法 |
| WO2007079203A2 (en) | 2005-12-28 | 2007-07-12 | 3M Innovative Properties Company | Treatment for cutaneous t cell lymphoma |
| US20090306388A1 (en) | 2006-02-10 | 2009-12-10 | Pfizer Inc. | Method for substituted ih-imidazo[4,5-c] pyridines |
| WO2007100634A2 (en) | 2006-02-22 | 2007-09-07 | 3M Innovative Properties Company | Immune response modifier conjugates |
| US8329721B2 (en) | 2006-03-15 | 2012-12-11 | 3M Innovative Properties Company | Hydroxy and alkoxy substituted 1H-imidazonaphthyridines and methods |
| WO2007106852A2 (en) | 2006-03-15 | 2007-09-20 | Coley Pharmaceutical Group, Inc. | Substituted fused[1,2]imidazo[4,5-c] ring compounds and methods |
| WO2007149802A2 (en) | 2006-06-19 | 2007-12-27 | 3M Innovative Properties Company | Formulation for delivery of immune response modifiers |
| US7906506B2 (en) | 2006-07-12 | 2011-03-15 | 3M Innovative Properties Company | Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods |
| US8124096B2 (en) | 2006-07-31 | 2012-02-28 | 3M Innovative Properties Company | Immune response modifier compositions and methods |
| US8178539B2 (en) | 2006-09-06 | 2012-05-15 | 3M Innovative Properties Company | Substituted 3,4,6,7-tetrahydro-5H-1,2a,4a,8-tetraazacyclopenta[cd]phenalenes and methods |
| US20080149123A1 (en) | 2006-12-22 | 2008-06-26 | Mckay William D | Particulate material dispensing hairbrush with combination bristles |
-
2004
- 2004-10-01 BR BRPI0414867 patent/BRPI0414867A/pt not_active IP Right Cessation
- 2004-10-01 TW TW93129933A patent/TW200526656A/zh unknown
- 2004-10-01 NZ NZ546274A patent/NZ546274A/en not_active IP Right Cessation
- 2004-10-01 AU AU2004315876A patent/AU2004315876B2/en not_active Ceased
- 2004-10-01 KR KR20067008540A patent/KR20060120069A/ko not_active Ceased
- 2004-10-01 KR KR20127011556A patent/KR101494056B1/ko not_active Expired - Fee Related
- 2004-10-01 MY MYPI20044029 patent/MY146124A/en unknown
- 2004-10-01 SG SG200900237-9A patent/SG149829A1/en unknown
- 2004-10-01 JP JP2006534174A patent/JP2007508305A/ja not_active Withdrawn
- 2004-10-01 ES ES04821468.8T patent/ES2584863T3/es not_active Expired - Lifetime
- 2004-10-01 AR ARP040103583 patent/AR046172A1/es unknown
- 2004-10-01 EP EP04821468.8A patent/EP1696912B1/en not_active Expired - Lifetime
- 2004-10-01 CA CA 2540598 patent/CA2540598C/en not_active Expired - Fee Related
- 2004-10-01 WO PCT/US2004/032480 patent/WO2005079195A2/en not_active Ceased
-
2006
- 2006-03-30 IL IL17464706A patent/IL174647A/en not_active IP Right Cessation
-
2012
- 2012-01-26 US US13/359,213 patent/US9145410B2/en not_active Expired - Fee Related
- 2012-07-23 JP JP2012162368A patent/JP5746108B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US9145410B2 (en) | 2015-09-29 |
| AU2004315876B2 (en) | 2011-05-26 |
| MY146124A (en) | 2012-06-29 |
| IL174647A (en) | 2010-11-30 |
| WO2005079195A3 (en) | 2006-08-10 |
| EP1696912A4 (en) | 2009-06-03 |
| CA2540598C (en) | 2013-09-24 |
| WO2005079195A2 (en) | 2005-09-01 |
| BRPI0414867A (pt) | 2006-11-21 |
| KR101494056B1 (ko) | 2015-02-16 |
| JP5746108B2 (ja) | 2015-07-08 |
| ES2584863T3 (es) | 2016-09-29 |
| JP2012236838A (ja) | 2012-12-06 |
| JP2007508305A (ja) | 2007-04-05 |
| AU2004315876A1 (en) | 2005-09-01 |
| KR20060120069A (ko) | 2006-11-24 |
| NZ546274A (en) | 2009-12-24 |
| TW200526656A (en) | 2005-08-16 |
| IL174647A0 (en) | 2006-08-20 |
| EP1696912B1 (en) | 2016-05-11 |
| KR20120066062A (ko) | 2012-06-21 |
| SG149829A1 (en) | 2009-02-27 |
| CA2540598A1 (en) | 2005-09-01 |
| US20120121651A1 (en) | 2012-05-17 |
| EP1696912A2 (en) | 2006-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR046172A1 (es) | Pirazolopiridinas y sus analogos; composiciones farmaceuticas que los contienen y su uso en la inhibicion de la biosintesis de citocinas | |
| AR045529A1 (es) | Imidazoquinolinas sustituidas con grupos ariloxi o arilalquilenoxi | |
| AR046046A1 (es) | Imidazoquinolinas alcoxi sustituidas. composiciones farmaceuticas. | |
| AR053202A1 (es) | Pirazolpiridinas y analogos de las mismas como inmunomoduladores | |
| AR042635A1 (es) | Imidazoquinolinas arilsustituidas y composiciones farmaceuticas que las contienen | |
| AR048289A1 (es) | Eteres de anillos imidazo sulfona sustituidos. | |
| AR049331A1 (es) | Derivados de imidazopiridinas, imidazoquinolinas e iimidazonaftiridinas sustituidas con amidas como moduladores de biosintesis de citoquinas. composiciones farmaceuticas. | |
| AR043508A1 (es) | 1-amino 1-h-imidazoquinolinas y su uso como inmunomoduladores | |
| AR045260A1 (es) | Compuestos que contienen imidazo-oxima sustituidos | |
| AR046781A1 (es) | Derivados de imidazoquinolinas. composiciones farmaceuticas. | |
| AR080779A1 (es) | Pirrolopirazina como inhibidores quinasa, composiciones farmaceuticas que los contienen y sus aplicaciones | |
| AR086181A2 (es) | Metodo para preparar inhibidores macrociclicos inhibidores de serina proteasas del virus de la hepatitis c | |
| AR083367A1 (es) | Compuestos de tipo quinazolinona como antagonistas de crth | |
| AR077267A1 (es) | Derivados nitrogenados heterociclicos inhibidores selectivos de pi3k, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades inflamatorias y/o autoinmunes. | |
| AR077598A1 (es) | Compuestos heterociclicos fusionados como modulares de canales ionicos | |
| AR049706A1 (es) | Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| AR043199A1 (es) | Componentes heterociclicos utiles para el tratamiento de enfermedades inflamatorias y alergicas, proceso para su operacion y composicion farmaceutica que contiene dichos componentes | |
| AR068051A1 (es) | Compuestos moduladores de la pi3k quinasa,composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento del cancer. | |
| UY28578A1 (es) | Derivados de amida | |
| AR066617A1 (es) | Derivados de pirazol sustituidos con heteroarilo utiles para tratar trastornos hiperproliferativos y emfermedades asociadas con angiogenesis | |
| PE20030762A1 (es) | Compuestos heterociclicos como antagonistas nk1 | |
| AR048789A1 (es) | Derivados de oxazol y sus composiciones como moduladores de receptor activado de proliferador de peroxisoma (ppar) | |
| AR082889A1 (es) | Compuestos y composiciones para la inhibicion de nampt | |
| AR077463A1 (es) | Derivados de imidazo[1, 2 - a]pirazina y su uso en medicamentos para el tratamiento de enfermedades parasitarias |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |